Cancer Genetics Inc

Cancer Genetics — Q3 2015 Earnings Presentation

11 slides from Cancer Genetics's earnings presentation, Nov 10, 2015

  1. Slide 1: Q3 2015 Earnings Call

    November 10, 2015 Q3 2015 Earnings Call

  2. Slide 2: Forward-Looking Statements

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in

  3. Slide 3: 3rd Quarter 2015 Revenue Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call 3rd Quarter 2015 Revenue Highlights $6.9M PROFORMA REVENUE WITH RESPONSE ACQUISITION 24% REVENUE GROWTHFROM Q3 2014 Q3 TOTAL REVENUE GREW FROM $3.2M TO 2014 2015 * The proforma revenue numbers above may not be indicative of the consolidate

  4. Slide 4: Revenues By Category

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Revenues By Category 65% 29% 6% Q3 2015 $3.2 MN $4.0 MN BIOPHARMA SERVICES  Continued growth in contracts for future – now $34 MN  Entered into partnership with ICON to offer Cancer Genetics’ services $2.6 MN CLINICAL SERVICES  Closed a

  5. Slide 5: 3rd Quarter 2015 Financial Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call 3rd Quarter 2015 Financial Highlights  Q3 2015 revenues were $4.0 million, a 24% increase over Q3 2014 revenues of $3.2 million.  Revenue from Biopharma Services grew 35% , Clinical Services decreased slightly by 7% and Discovery Service

  6. Slide 6: Income Statement Items

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Income Statement Items ($ in Thousands) Q3 2015 Q3 2014 9 mos 2015 9 mos 2014 Revenue $4,000 $3,221 $12,556 $6,164 Gross Profit $897 $656 $3,213 $805 Gross Margin (%) 22% 20% 26% 13% Research & Development (R&D) $1,802 $1,390 $4,335 $3,093

  7. Slide 7: Highlights of Response Genetics Acquisition

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Highlights of Response Genetics Acquisition Response Genetics is an oncology-focused central laboratory with a specialty in solid tumors headquartered in Los Angeles, CA.  Closed on October 9, 2015  Core business in solid tumor molecular

  8. Slide 8: Tissue of Origin Competitor Comparison

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Tissue of Origin® Competitor Comparison CRITERIA Tissue of Origin® CancerTYPE ID™ Cancer Origin Test™ EXTERN A L REVIE W FDA CLEARED Yes No No MEDICARE COVERED Yes Yes Yes PEER-REVIEWED PUBLICATIONS 23 21 6 V A L ID A T IO N STUD Y NUMBER

  9. Slide 9: Proforma Revenue with Response Genetics

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Proforma Revenue with Response Genetics * The proforma revenue numbers above may not be indicative of the consolidated results in the future. Acquisition completed October 9, 2015. $6.6 $10.2 $12.6 $19.8 $16.7 $10.0 $26.4 $26.9 $22.6 2013

  10. Slide 10: Expense Synergies for Response Acquisition

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2015 Earnings Call Expense Synergies for Response Acquisition Management estimates expense savings of more than $5 million in the first year of acquisition  Consolidation of common functions including Billing, Accounting, Quality Assurance, Information Tech

  11. Slide 11: The Oncology Diagnostics Partner From Bench to Bedside

    THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 Fax: +1 919-465-0554 RALEIGH, NC LOS AN

Cancer Genetics — Q3 2015 Earnings Presentation on 6ix